financetom
Business
financetom
/
Business
/
Gaming firm GDEV's Q2 revenue beats analyst expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Gaming firm GDEV's Q2 revenue beats analyst expectations
Sep 2, 2025 5:39 AM

Overview

* GDEV ( GDEV ) Q2 revenue rises 13% yr/yr, beating analyst expectations

* Net income for Q2 increases to $17 mln from $15 mln in 2024

* Adjusted EBITDA for Q2 rises to $22 mln from $17 mln in 2024

Result Drivers

* IN-APP PURCHASES - Revenue increase driven by higher consumable in-app purchases, despite lower advertising bookings

* MARKETING EXPENSES - Selling and marketing expenses rose 11% due to testing new performance marketing areas

* NEGATIVE CASH FLOW - Operating cash flow turned negative due to decreased bookings and increased marketing expenses

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $120 mln $89.30

Revenue mln (2

Analysts

)

Q2 Net $17 mln

Income

Q2 $22 mln

Adjusted

EBITDA

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the software peer group is "buy"

* Wall Street's median 12-month price target for GDEV Inc ( GDEV ) is $70.00, about 79.3% above its August 29 closing price of $14.48

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 6 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Neurocrine Biosciences Says Late-Stage Movement Disorder Study Shows Ingrezza's Therapeutic Efficacy at Lowest Available Dose
Neurocrine Biosciences Says Late-Stage Movement Disorder Study Shows Ingrezza's Therapeutic Efficacy at Lowest Available Dose
Oct 17, 2025
09:29 AM EDT, 10/17/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Friday that a new post-hoc analysis of a late-stage study showed clinically meaningful improvements in tardive dyskinesia symptoms in patients treated with Ingrezza at the lowest available dose of 40 mg. The company said 90% of participants who received continuous treatment for 48 weeks improved by at...
AbbVie Closes Bretisilocin Acquisition
AbbVie Closes Bretisilocin Acquisition
Oct 17, 2025
09:28 AM EDT, 10/17/2025 (MT Newswires) -- AbbVie ( ABBV ) said Friday it has closed the acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate bretisilocin. Bretisilocin is a psychedelic compound in phase 2 clinical development for the treatment of patients with moderate to severe major depressive disorder, AbbVie ( ABBV ) said. ...
Visionary Completes Controlling Stake in Sikang Health Industry Joint Venture Platform, Deepening Global Layout of TCM Health Preservation
Visionary Completes Controlling Stake in Sikang Health Industry Joint Venture Platform, Deepening Global Layout of TCM Health Preservation
Oct 17, 2025
TORONTO, Oct. 17, 2025 /PRNewswire/ -- Visionary Holdings Inc. ( GV ) , a Nasdaq-listed enterprise, announced today that it has completed the equity adjustment of Sikang (Guangzhou) Health Industry Investment Co., Ltd. (hereinafter referred to as the Joint Venture Company), a joint venture established with Guangzhou Sikang Investment Holding Co., Ltd. (hereinafter referred to as Guangzhou Sikang), and officially...
OBOOK Shares Fall Pre-Bell After Nasdaq Listing
OBOOK Shares Fall Pre-Bell After Nasdaq Listing
Oct 17, 2025
09:27 AM EDT, 10/17/2025 (MT Newswires) -- OBOOK ( OWLS ) shares were down 38% in Friday premarket activity, continuing their losses after the company's Nasdaq listing on Thursday. The company's shares closed at $55.55 on Thursday, down 18% from their $68 per share opening price. The company said that at the closing price on Thursday its market capitalization was...
Copyright 2023-2026 - www.financetom.com All Rights Reserved